摘要
Programmed cell death 1 ligand 1 (PD-L1) has been approved as predictive biomarker for non-small-cell lung cancer (NSCLC) patients treated with PD-(L)1 blockade therapy. The clinical/genomic features associated with PD-L1 are not well studied. Genomic profiling of tumor biopsies from 883 Chinese NSCLC patients was performed by targeted next-generation sequencing. Immunohistochemical analysis was conducted to evaluate PD-L1 expression levels using antibodies Dako 22C3 and 28-8, respectively. Our study showed distinct correlation between PD-L1 expression and clinical/genomic characteristics when using different PD-L1 antibodies and in different histological subtypes including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), respectively. PD-L1 high expression (22C3) was associated with male and lymph node metastasis only in ADC patients. Furthermore, mutations of TP53 and KRAS, KIF5B-RET fusion, copy number gains of PD-L1 and PD-L2, and arm-level amplifications of chr.12p were significantly associated with PD-L1 positive status in ADC patients. For SCC patients, the gain of EGFR and MDM2 and loss of PTPRD were negatively associated with PD-L1 expression. We also compared our results with other studies and found conflicting results presumably because of the multiplicity of antibody clones and platforms, the difference of cutoffs for assigning PD-L1 expression levels, and the variation in study populations. Our study can help to understand the utility and validity of PD-L1 as biomarker of response to immune checkpoint inhibitors.
学科与关键词
- Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patientsLi, Kang; Liu, Jun; Wu, Lin; Xiao, Yajie; Li, Jia; Du, Haijian; Zhao, Zhikun; Sun, Chao; Zhao, Yongtian; Yang, Jie; Wu, Dongfang; Zhao, Zhuxiang*; Chen, Bolin*Cancer Cell International, 2022, 22(1): 138.被引 7
- In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.Kang, Li; Liu, Jun; Li, Jia; Wu, Lin; Xiao, Yajie; Du, Haijian; Zhao, Zhikun; Li, Xiaoting; Wu, Dongfang; Zhao, Zhuxiang; Chen, BolinVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
- Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlationsLi, Kai; Cao, Li; Li, Cheukfai; Wu, Jundong; Chen, Bo; Zhang, Guochun; Li, Xueri; Wen, Lingzhu; Jia, Minghan; Wei, Guangnan; Lin, Jiali; Li, Yingzi; Zhang, Yuchen; Mok, Hsiaopei; Ren, Chongyang; Wang, Yulei; Qi, Xiaofang; Guo, Lijie; Che, Yue; Liao, Ning*Cancer Medicine, 2023, 12(5): 5195-5208.
